Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

(2011) Lokesh Jain et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Evaluation of Tumoral Response to Antiangiogenic Therapy by Arterial Spin Labeling Perfusion Magnetic Resonance Imaging and Susceptibility Weighted Imaging in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

(2011) Slim Fellah et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients

(2011) Michel Tod et al.   PHARMACEUTICAL RESEARCH

Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer

(2010) Andrew R. Reynolds   Dose-Response

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

(2010) Lokesh Jain et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

(2010) Keith C Bible et al.   LANCET ONCOLOGY

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

(2010) Patrick A. Ott et al.   PLoS One

A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer

(2009) J. Michels et al.   ANNALS OF ONCOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

(2009) R. K. Amaravadi et al.   CLINICAL CANCER RESEARCH

The pathogenic mechanisms of sorafenib-related diarrhea: Preliminary results

(2009) E.C. Lauritano et al.   DIGESTIVE AND LIVER DISEASE

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

(2009) B. Blanchet et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS